0001062993-22-002729.txt : 20220204
0001062993-22-002729.hdr.sgml : 20220204
20220204192852
ACCESSION NUMBER: 0001062993-22-002729
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220202
FILED AS OF DATE: 20220204
DATE AS OF CHANGE: 20220204
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ortega-Valle Marta
CENTRAL INDEX KEY: 0001908352
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39894
FILM NUMBER: 22595169
MAIL ADDRESS:
STREET 1: C/O GREENLIGHT BIOSCIENCES HOLDINGS, PBC
STREET 2: 200 BOSTON AVENUE, SUITE 3100
CITY: MEDFORD
STATE: MA
ZIP: 02155
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: GreenLight Biosciences Holdings, PBC
CENTRAL INDEX KEY: 0001822691
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 851914700
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 BOSTON AVENUE
STREET 2: SUITE 3100
CITY: MEDFORD
STATE: MA
ZIP: 02155
BUSINESS PHONE: (617) 616-8188
MAIL ADDRESS:
STREET 1: 200 BOSTON AVENUE
STREET 2: SUITE 3100
CITY: MEDFORD
STATE: MA
ZIP: 02155
FORMER COMPANY:
FORMER CONFORMED NAME: Environmental Impact Acquisition Corp
DATE OF NAME CHANGE: 20200826
4
1
form4.xml
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
X0306
4
2022-02-02
0001822691
GreenLight Biosciences Holdings, PBC
GRNA
0001908352
Ortega-Valle Marta
C/O GREENLIGHT BIOSCIENCES HOLDINGS, PBC
200 BOSTON AVENUE, SUITE 3100
MEDFORD
MA
02155
0
1
0
0
Chief Business Officer
Stock Option (Right to Buy)
0.24
2022-02-02
4
A
0
29798
A
2022-06-08
Common Stock
29798
29798
D
Stock Option (Right to Buy)
0.28
2022-02-02
4
A
0
105266
A
2023-12-13
Common Stock
105266
105266
D
Stock Option (Right to Buy)
0.35
2022-02-02
4
A
0
106098
A
2025-07-22
Common Stock
106098
106098
D
Stock Option (Right to Buy)
0.98
2022-02-02
4
A
0
247727
A
2030-09-24
Common Stock
247727
247727
D
Stock Option (Right to Buy)
0.98
2022-02-02
4
A
0
259584
A
2030-12-01
Common Stock
259584
259584
D
100% of the shares subject to this option are fully vested and exercisable.
This option was issued pursuant to the terms of a business combination agreement involving the Issuer and GreenLight Biosciences, Inc. in exchange for a comparable option previously issued by such company.
100% of the shares subject to this option are fully vested and exercisable.
100% of the shares subject to this option are fully vested and exercisable.
20% of the shares underlying the option vested or shall vest on September 24, 2021 and the remainder of the shares vested or shall vest in 48 equal monthly installments thereafter, starting October 24, 2021.
25% of the shares underlying the option vested or shall vest on December 1, 2021 and the remainder of the shares vested or shall vest in 36 equal monthly installments thereafter, starting January 1, 2022.
/s/ David Kennedy, Attorney-in-fact
2022-02-04